Engineers at the forefront,

Patients at the center.

Omnia Medical creates innovative implants designed to help improve patient care and surgical outcomes. Our results speak for themselves. Trusted by patients and physicians, Omnia is committed to creating solutions that work for all.

Patient Education

For Physicians

Our Solutions

SI Joint Stabilization

PsiF DNA →

Posterior SI Procedure Kit

PsiF90 →

Dynamic SI Guidance

PsiFGuard →

Posterior SI Fusion

PsiF →

Cervical IBD

TiBrid C →

Standalone ALIF IBD

TiBrid SA →

Rotatable IBD

Rotary →

Demineralized Bone Matrix

DBLogix →

Allogenic Bone Scaffold

CeLLogix →

Vertebral Body Replacement

Boxcar →

About Omnia Medical

Revolutionizing healthcare. Optimizing patient outcomes. These are the founding principles of Omnia Medical. Our cutting-edge implants are at the forefront of advanced medical care, empowering surgeons to practice to their full potential and provide exceptional patient care.

Learn more

Trusted by the Best

Latest News & Events

Featured

Omnia Medical Announces Commercial Launch of FDA-Cleared PsiF DNA™ System

Omnia Medical, a leader in surgical solutions for spine and interventional pain, has officially announced the commercial launch of its PsiF DNA™ Sacroiliac Joint Stabilization System.

Following its FDA 510(k) clearance in May 2025 and a successful alpha launch, the system is now broadly available for treating degenerative sacroiliitis and joint disruptions.

Omnia Medical Reaches Settlement as PainTEQ Admits Breach and Patent Infringement

After several years of litigation, Omnia and PainTEQ have fully and finally resolved all of the issues between them. As part of that resolution PainTEQ agreed to admit that it breached the parties’ Stocking Agreement, used Omnia’s PsiF trademark, and that PainTEQ’s Gen 2 cannula infringed Omnia’s D232 design patent.

Omnia Files Response in Opposition to PainTEQ’s Motion for Summary Judgment

Relying heavily on testimony provided during the sworn depositions of Sean LaNeve, Chris Girsch, and Charles Girsch, as well as corporate representatives of RTI and Avalign, Omnia gave a glimpse into some of the many facts and arguments it intends to use during trial, which is currently set for October 7, 2024.